Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

NIH 3OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2CNS 2Sarcoma 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × carotuximab × Genitourinary × Clear all
NCT01727089 2018-08-28

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
59 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT01090765 2018-05-22

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 17 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01328574 2017-01-13

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
13 enrolled 15 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡